Molecular Profiling for Precision Oncology: Moving Beyond Feasibility and Safety.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 41534035.
- Also identified by DOI 10.1200/JCO-25-02642 and PMC identifier 12810768.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In the article that accompanies this editorial, Sicklick et al. provide the results of their work to match next-generation sequencing to novel therapeutic drugs/combinations in metastatic cancer patients. While one of the largest studies of its kind, this application of “precision medicine” is ultimately limited by the need for a randomized trial to show that using molecular data for a very heterogeneous group of patients identifies therapies that are superior to existing standard-of-care agents.